JP2009536191A5 - - Google Patents

Download PDF

Info

Publication number
JP2009536191A5
JP2009536191A5 JP2009508544A JP2009508544A JP2009536191A5 JP 2009536191 A5 JP2009536191 A5 JP 2009536191A5 JP 2009508544 A JP2009508544 A JP 2009508544A JP 2009508544 A JP2009508544 A JP 2009508544A JP 2009536191 A5 JP2009536191 A5 JP 2009536191A5
Authority
JP
Japan
Prior art keywords
compound
compound according
formula
patient
cell proliferation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009508544A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009536191A (ja
JP5225264B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2007/002471 external-priority patent/WO2007129226A2/en
Publication of JP2009536191A publication Critical patent/JP2009536191A/ja
Publication of JP2009536191A5 publication Critical patent/JP2009536191A5/ja
Application granted granted Critical
Publication of JP5225264B2 publication Critical patent/JP5225264B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009508544A 2006-05-09 2007-05-09 細胞増殖障害の処置 Expired - Fee Related JP5225264B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79910306P 2006-05-09 2006-05-09
US60/799,103 2006-05-09
PCT/IB2007/002471 WO2007129226A2 (en) 2006-05-09 2007-05-09 Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders

Publications (3)

Publication Number Publication Date
JP2009536191A JP2009536191A (ja) 2009-10-08
JP2009536191A5 true JP2009536191A5 (enExample) 2011-09-08
JP5225264B2 JP5225264B2 (ja) 2013-07-03

Family

ID=38668152

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009508544A Expired - Fee Related JP5225264B2 (ja) 2006-05-09 2007-05-09 細胞増殖障害の処置

Country Status (12)

Country Link
US (3) US20090306214A1 (enExample)
EP (1) EP2026775B1 (enExample)
JP (1) JP5225264B2 (enExample)
AU (1) AU2007246779B2 (enExample)
CA (1) CA2651375C (enExample)
DK (1) DK2026775T3 (enExample)
ES (1) ES2542344T3 (enExample)
HU (1) HUE026820T2 (enExample)
IL (1) IL195152A (enExample)
PL (1) PL2026775T3 (enExample)
PT (1) PT2026775E (enExample)
WO (1) WO2007129226A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2535975T3 (es) * 2002-10-03 2015-05-19 Novaremed Ltd. Compuestos para su uso en el tratamiento de enfermedades autoinmunitarias, enfermedades inmunoalérgicas y rechazo de trasplantes de órganos o tejidos
US7674829B2 (en) * 2004-03-26 2010-03-09 Novaremed Limited Compounds for the treatment of AIDS and other viral diseases
GB0804213D0 (en) 2008-03-06 2008-04-16 New Era Biotech Ltd A method of printing or preventing pain
PL2475361T3 (pl) * 2009-09-09 2020-07-13 Novaremed Ltd. N-podstawione benzenopropanoamidy do stosowania w leczeniu bólu i stanu zapalnego
US8802734B2 (en) 2009-09-09 2014-08-12 Novaremed Limited Method of treating or preventing pain
IL291945B2 (en) 2012-11-01 2025-11-01 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
WO2014151386A1 (en) 2013-03-15 2014-09-25 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
SG10201709926VA (en) 2013-05-30 2017-12-28 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX389256B (es) 2013-10-04 2025-03-20 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP4066834A1 (en) 2014-03-19 2022-10-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN108349985A (zh) 2015-09-14 2018-07-31 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA3028718A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
CA3159348A1 (en) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1908322A (en) * 1932-04-07 1933-05-09 Claude R Cook Weed puller
US2908691A (en) * 1958-07-14 1959-10-13 Searle & Co Hydroxyphenalkylaminoalkylindoles and ethers corresponding thereto
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5539122A (en) * 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
ES2535975T3 (es) * 2002-10-03 2015-05-19 Novaremed Ltd. Compuestos para su uso en el tratamiento de enfermedades autoinmunitarias, enfermedades inmunoalérgicas y rechazo de trasplantes de órganos o tejidos
US7674829B2 (en) * 2004-03-26 2010-03-09 Novaremed Limited Compounds for the treatment of AIDS and other viral diseases

Similar Documents

Publication Publication Date Title
JP2009536191A5 (enExample)
CA2651375A1 (en) Treatment of cell proliferative disorders
JP2017525730A5 (enExample)
JP2012506872A5 (enExample)
JP2011057693A5 (enExample)
JP2013509429A5 (enExample)
JP2008528671A5 (enExample)
JP2010540556A5 (enExample)
JP2011518202A5 (enExample)
JP2011046708A5 (enExample)
JP2008539267A5 (enExample)
JP2012522841A5 (enExample)
JP2012509279A5 (enExample)
RU2011124894A (ru) Триазолотиадиазоловый ингибитор протеинкиназы с-мет
JP2017503753A5 (enExample)
JP2004531478A5 (enExample)
JP2007502832A5 (enExample)
JP2013537240A5 (enExample)
JP2018521969A (ja) 医薬用共結晶及びその用途
JP2013544892A5 (enExample)
RU2012150501A (ru) Противораковые стероидные лактоны, ненасыщенные в положении 7(8)
JP2009502777A5 (enExample)
JP2012505905A5 (enExample)
JP2014511897A5 (enExample)
JP5289310B2 (ja) 微小管破壊剤及びそれを含有する癌細胞増殖抑制剤